Scalper1 News
Drugmakers showed their appetite for orphan-disease drugs Monday, with two billion-dollar-plus deals sending stocks soaring. Israeli drug giant Teva Pharmaceutical Industries (TEVA) agreed to pay $101 a share in cash for Auspex Pharmaceuticals (ASPX), a development-stage biotech that plans to apply for approval of its Huntington’s disease treatment in the next few months. The company is also developing treatments for other central-nervous-system Scalper1 News
Scalper1 News